Skip to content
DataLookout
Menu

NCT07899801

A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

Part 1 Safety Lead-In Cohort: Treatment with Zanidatamab + ZongertinibExperimental

Participants will receive treatment on an outpatient basis

Part 2 Expansion Cohort: Treatment with Zanidatamab + ZongertinibExperimental

Participants will receive treatment on an outpatient basis

Drugs: Zanidatamab, Zongertinib

Sites

1 site in 1 country

  • UT MD AndersonHouston, Texas, United States